Comparison Result:
PDF: Document Number: M-US-00026466(v1.0)
Email: <!doctype html><html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" lang="en-US" xml:lang="en-US"><head> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1"> <title>ENSPRYNG (satralizumab-mwge)</title> <style type="text/css">
PDF: Sender Name: ENSPRYNG (satralizumab-mwge)
Email: .ghost-link img {
PDF: Sender Email: info@info.genentech.com 
Email:   display: inline-block;
PDF: info@mail.genentech.com
Email: }
PDF: info@mail.genentech.com
Email: </style> <!--[if gte mso 9]><xml><o:OfficeDocumentSettings><o:AllowPNG/><o:PixelsPerInch>96</o:PixelsPerInch></o:OfficeDocumentSettings></xml> <style>sup,sub{font-size:100% !important;}table{border-collapse:collapse !important;border-spacing:0 !important;}
PDF: To: John Doe <john.doe@example.com>
Email: </style><![endif]--> <style type="text/css">body,td{font-family:Arial,sans-serif;font-size:16px;color:#000000;line-height:22px;}table{font-size:inherit;}*{line-height:inherit;}table td{border-collapse:collapse;}a[x-apple-data-detectors]{color:inherit!important;text-decoration:none!important;font-size:inherit!important;font-family:inherit!important;font-weight:inherit!important;line-height:inherit!important;}.mobile-only{display:none;max-height:0px;overflow:hidden;mso-hide:all;}.mobile-only table{mso-hide:all;}
PDF: Subject Line Option 1: When treating NMOSD, dull moments aren’t such a bad thing
Email: @media only screen and (max-width:37.5em){.main-table{width:100%!important;}.main-td{min-width:initial!important;}.main-table table{width:100%!important;margin:0 auto!important;}.block,.content,.safety{display:block;}.desktop-only{display:none!important;}img{max-width:100%!important;height:auto!important;}.mobile-only{display:block!important;max-height:none!important;overflow:visible!important;}.width-auto{width:auto!important;height:auto!important;}.m-pb20{padding-bottom:20px!important;}.m-pr0{padding-right:0!important;}.m-logo{width:108px!important;height:auto!important;}.content{padding-right:35px!important;padding-left:30px!important;}.safety-cont,.rr-safety,.footer{padding-right:35px!important;padding-left:35px!important;}.rr-safety{border-left:none!important;} }
PDF: Subject Line Option 2: Embrace the ordinary with ENSPRYNG® (satralizumab)
Email: </style> <meta charset="ISO-8859-1"> </head> <body style="-webkit-text-size-adjust: 100%; -ms-text-size-adjust: 100%; margin: 0; padding: 0; width: 100%;"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" id="backgroundTable" width="100%" style="margin: 0; padding: 0; width: 100%; line-height: 100%;"> <tbody> <tr> <td class="main-td" style="font-family: Arial,sans-serif; font-size: 16px; color: #000000; line-height: 22px; min-width: 640PX;"> <table class="main-table" align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="640" style="width:640PX;"> <tbody> <tr> <td class="preheader" style="padding-right: 25px; padding-left: 25px; padding-top: 10px; padding-bottom: 10px; background-color: #F0F0F0;" bgcolor="#F0F0F0"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td style="font-size: 12px; line-height: 16px; color: #505050;"><span id="preheader">Learn more about this treatment option</span> </td> <td class="webversion pl5" align="right" width="95" style="padding-left: 5px; font-size: 12px; line-height: 16px; color: #505050; width: 95px;"> <a href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92ee&e=cDE9JTQwOUY2bXd2eFQ0REsxaWI3blBUUCUyRjVlRWVJRjV3Z1FGYURNNlI3aUdjbFRNJTNE&s=vUB5TYkvJzj3zMrW3rhdGjUZYZvPG0JNJibQBHwAygE" style="color: #003087; text-decoration: underline; font-weight: bold;">View&nbsp;in&nbsp;browser</a> </td> </tr> </tbody> </table> </td> </tr> <tr> <td class="header" style="padding-right: 25px; padding-left: 25px; padding-top: 20px; padding-bottom: 20px;"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td valign="top"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="pr5" style="padding-right: 5px;"> <a class="ghost-link" href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92ef&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=vx_m_IYWyliRBj5SFJbAuA5npGHqXoSDp6hwmbzaMYg" style="text-decoration: underline; color: #ED1556; font-weight: bold; font-size: 14px; line-height: 18px;"><img class="m-logo" src="https://aem.gene.com/content/dam/gene/email/enspryng/hcp/ens-h-nan-0002-1/logo-ens-2x.png" alt="Enspryng logo" width="122" height="94" style="outline: none; text-decoration: none; -ms-interpolation-mode: bicubic; font-size: 10px; border: none; display: inline-block;"></a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> <td> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="pb5" align="right" style="padding-bottom: 5px;"> <a href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92f0&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=aOr5cGxbf19j46r_Pu73lrDb9jXUSXa87CexujLhJR8" style="text-decoration: underline; color: #ED1556; font-weight: bold; font-size: 14px; line-height: 18px;">Prescribing Information</a> </td> </tr> <tr> <td align="right"> <a href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92f1&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=CVLRRH7lt7_Wz9EQ2SeZDlWcGAnHDU3FajgPjsy1MgE" style="text-decoration: underline; color: #ED1556; font-weight: bold; font-size: 14px; line-height: 18px;">Important Safety Information</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> <tr> <td class="desktop-only"> <a href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92f2&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=WsYvAQkLaSTXmHNmJJvG5f4Y98xC1Gde2hpKyupbQZ0" style="text-decoration: underline;"><img src="https://aem.gene.com/content/dam/gene/email/enspryng/hcp/ens-h-nan-0002-1/header-desktop-2x.png" alt="ENSPRYNG" width="640" height="240" style="display: block; outline: none; text-decoration: none; -ms-interpolation-mode: bicubic; font-size: 10px; border: none;"></a> </td> </tr> <tr class="mobile-only" style="display: none; max-height: 0px; overflow: hidden;"> <td class="mobile-only" style="display: none; max-height: 0px; overflow: hidden;"> <div class="mobile-only" style="display: none; max-height: 0px; overflow: hidden;"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td> <a href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92f3&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=zQ7Z5kbW_4C87yIn8UdWuskm5G828tlO4TF1CsPOt7k" style="text-decoration: underline;"><img class="width-auto" src="https://aem.gene.com/content/dam/gene/email/enspryng/hcp/ens-h-nan-0002-1/header-mobile-2x.png" alt="ENSPRYNG" width="0" height="0" style="display: block; outline: none; text-decoration: none; -ms-interpolation-mode: bicubic; font-size: 10px; border: none;"></a> </td> </tr> </tbody> </table> </div> </td> </tr> <tr> <td class="pt50" style="padding-top: 50px;"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="content" valign="top" style="padding-right: 25px; padding-left: 20px; padding-bottom: 30px;"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="h2 pr0 pb15" style="font-size: 20px; line-height: 24px; color: #242A74; font-weight: bold; padding-bottom: 15px; padding-left: 5px; padding-right: 0;">Life with NMOSD is unpredictable<sup style="line-height: 0; font-size: 75%;">1-4</sup> </td> </tr> <tr> <td class="p" style="padding-bottom: 15px; padding-left: 5px; padding-right: 5px;">ENSPRYNG helps by reducing the risk of relapse in adults with AQP4-IgG(+) NMOSD, whether they were treatment naïve or previously treated. </td> </tr> <tr> <td class="h2 pb15" style="font-size: 20px; line-height: 24px; color: #242A74; font-weight: bold; padding-bottom: 15px; padding-left: 5px; padding-right: 5px;">ENSPRYNG is the first and only FDA-approved anti-IL-6 receptor monoclonal antibody for AQP4-IgG(+) NMOSD<sup style="line-height: 0; font-size: 75%;">1,5</sup> </td> </tr> <tr> <td class="p" style="padding-bottom: 15px; padding-left: 5px; padding-right: 5px;">Unlike other treatments, ENSPRYNG blocks the IL-6 receptor, allowing for modulation of the immune system to address key drivers of NMOSD.<sup style="line-height: 0; font-size: 75%;">1,6,7</sup>* </td> </tr> <tr> <td class="ul footnote pb25" style="font-size: 11px; line-height: 13px; padding-bottom: 25px;"> <table role="presentation" border="0" cellpadding="0" cellspacing="0"> <tbody> <tr> <td class="li" valign="top" style="width: 1px; font-size: 11px; line-height: 13px;" width="1">* </td> <td style="font-size: 11px; line-height: 13px; width: 100%;" width="100%">The precise mechanism by which ENSPRYNG exerts therapeutic effects in NMOSD is unknown. </td> </tr> </tbody> </table> </td> </tr> <tr> <td class="pl5 pb30" style="padding-bottom: 30px; padding-left: 5px;"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="light-blue-box" style="padding-right: 30px; padding-left: 30px; padding-top: 15px; padding-bottom: 15px; background-color: #F4FBFD; border-radius: 30px;" bgcolor="#F4FBFD"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="pb15" align="center" style="padding-bottom: 15px;"> <img src="https://aem.gene.com/content/dam/gene/email/enspryng/hcp/ens-h-nan-0002-1/icon-increase-2x.png" alt width="80" height="81" style="display: block; outline: none; text-decoration: none; -ms-interpolation-mode: bicubic; font-size: 10px;"> </td> </tr> <tr> <td class="p blue" align="center" style="color: #242A74; padding-bottom: 15px; padding-left: 5px; padding-right: 5px;"><strong>IL-6 levels are elevated</strong> in NMOSD and may be indicative of relapse&mdash;during a 2-year follow-up, higher baseline IL-6 levels correlated with risk of clinical relapse and their&nbsp;severity.<sup style="line-height: 0; font-size: 75%;">8</sup> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> <tr> <td class="pl5 pb20" style="padding-bottom: 20px; padding-left: 5px;"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="light-blue-box" style="padding-right: 30px; padding-left: 30px; padding-top: 15px; padding-bottom: 15px; background-color: #F4FBFD; border-radius: 30px;" bgcolor="#F4FBFD"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="pb15" align="center" style="padding-bottom: 15px;"> <img src="https://aem.gene.com/content/dam/gene/email/enspryng/hcp/ens-h-nan-0002-1/icon-decrease-2x.png" alt width="80" height="81" style="display: block; outline: none; text-decoration: none; -ms-interpolation-mode: bicubic; font-size: 10px;"> </td> </tr> <tr> <td class="p blue" align="center" style="color: #242A74; padding-bottom: 15px; padding-left: 5px; padding-right: 5px;">By targeting IL-6 signaling, ENSPRYNG is thought to <strong>help decrease inflammation</strong>, BBB permeability, and astrocyte injury&mdash;all key drivers of AQP4-IgG(+) NMOSD.<sup style="line-height: 0; font-size: 75%;">1,3,9</sup>* </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> <tr> <td class="pl5 pb30" align="left" style="padding-bottom: 30px; padding-left: 5px;"> <div> <!--[if mso]><v:roundrect xmlns:v="urn:schemas-microsoft-com:vml" xmlns:w="urn:schemas-microsoft-com:office:word" href="https://www.enspryng-hcp.com/about-nmosd/how-it-works.html?c=ens-195d33da064" style="height:36px;v-text-anchor:middle;width:165px;" arcsize="83%" strokecolor="#ED1556" fillcolor="#ED1556" strokeweight="1px"><w:anchorlock/><center style="color:#ffffff;font-family:Arial,sans-serif;font-size:13px;font-weight:bold;">WATCH MOA VIDEO</center></v:roundrect><![endif]--> <a href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92f4&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=rQXOaYtwM6xZPvFRVpES_aPTvByy8Y6TX1RCCWRo0bA" style="background-color: #ED1556; border: 1px solid #ED1556; border-radius: 30px; color: #ffffff; display: inline-block; font-family: Arial,sans-serif; font-size: 13px; font-weight: bold; line-height: 36px; text-align: center; text-decoration: none; width: 165px; -webkit-text-size-adjust: none; mso-hide: all;">WATCH MOA VIDEO</a> </div> </td> </tr> <tr> <td class="h2 pb15" style="font-size: 20px; line-height: 24px; color: #242A74; font-weight: bold; padding-bottom: 15px; padding-left: 5px; padding-right: 5px;">ENSPRYNG has a well-studied safety profile with a median exposure of 5 years<sup style="line-height: 0; font-size: 75%;">10&dagger;</sup> </td> </tr> <tr> <td class="p pb25" style="padding-bottom: 25px; padding-left: 5px; padding-right: 5px;">The rates of serious AEs were similar between ENSPRYNG and placebo in two phase 3 clinical trials<sup style="line-height: 0; font-size: 75%;">3,4,11&Dagger;</sup> </td> </tr> <tr class="mobile-only" style="display: none; max-height: 0px; overflow: hidden;"> <td class="mobile-only" style="display: none; max-height: 0px; overflow: hidden;"> <div class="mobile-only" style="display: none; max-height: 0px; overflow: hidden;"> <img class="width-auto pb25" src="https://aem.gene.com/content/dam/gene/email/enspryng/hcp/ens-h-nan-0002-1/graphic-chart-mobile-v2-2x.png" alt width="0" height="0" style="display: block; outline: none; text-decoration: none; -ms-interpolation-mode: bicubic; font-size: 10px; padding-bottom: 25px;"> </div> </td> </tr> <tr> <td class="desktop-only pb25" align="center" style="padding-bottom: 25px;"> <img src="https://aem.gene.com/content/dam/gene/email/enspryng/hcp/ens-h-nan-0002-1/graphic-chart-desktop-2x.png" alt width="330" height="202" style="display: block; outline: none; text-decoration: none; -ms-interpolation-mode: bicubic; font-size: 10px;"> </td> </tr> <tr> <td class="ul footnote pb30" style="font-size: 11px; line-height: 13px; padding-bottom: 30px;"> <table role="presentation" border="0" cellpadding="0" cellspacing="0"> <tbody> <tr> <td class="li" valign="top" style="width: 1px; font-size: 11px; line-height: 13px;" width="1"><sup style="line-height: 0; font-size: 75%;">&dagger;</sup> </td> <td class="pb15" style="padding-bottom: 15px; font-size: 11px; line-height: 13px; width: 100%;" width="100%">Median ENSPRYNG exposure of 5 years in SAkuraMoon. SAkuraMoon is a single-arm, open-label study that enrolled patients who had completed the double-blind periods and open-label extensions of SAkuraStar and SAkuraSky.<sup style="line-height: 0; font-size: 75%;">10</sup> </td> </tr> <tr> <td class="li" valign="top" style="width: 1px; font-size: 11px; line-height: 13px;" width="1"><sup style="line-height: 0; font-size: 75%;">&Dagger;</sup> </td> <td style="font-size: 11px; line-height: 13px;">The safety population included patients who received at least 1 dose of ENSPRYNG or placebo and included AQP4-seropositive and AQP4-seronegative patients.<sup style="line-height: 0; font-size: 75%;">3,4</sup> </td> </tr> </tbody> </table> </td> </tr> <tr> <td class="pl5 pb30" align="left" style="padding-bottom: 30px; padding-left: 5px;"> <div> <!--[if mso]><v:roundrect xmlns:v="urn:schemas-microsoft-com:vml" xmlns:w="urn:schemas-microsoft-com:office:word" href="https://www.enspryng-hcp.com/side-effects/summary.html?c=ens-195d33da064" style="height:36px;v-text-anchor:middle;width:165px;" arcsize="83%" strokecolor="#ED1556" fillcolor="#ED1556" strokeweight="1px"><w:anchorlock/><center style="color:#ffffff;font-family:Arial,sans-serif;font-size:13px;font-weight:bold;">VIEW SAFETY DATA</center></v:roundrect><![endif]--> <a href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92f5&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=IvaG3x-GBrxOpFUH31yEiuPk27OYJtSmKSogc4qzdsI" style="background-color: #ED1556; border: 1px solid #ED1556; border-radius: 30px; color: #ffffff; display: inline-block; font-family: Arial,sans-serif; font-size: 13px; font-weight: bold; line-height: 36px; text-align: center; text-decoration: none; width: 165px; -webkit-text-size-adjust: none; mso-hide: all;">VIEW SAFETY DATA</a> </div> </td> </tr> <tr> <td class="h2 pb15" style="font-size: 20px; line-height: 24px; color: #242A74; font-weight: bold; padding-bottom: 15px; padding-left: 5px; padding-right: 5px;">Get your patients started today! </td> </tr> <tr> <td class="ul pl5" style="padding-bottom: 15px; padding-left: 5px;"> <table role="presentation" border="0" cellpadding="0" cellspacing="0"> <tbody> <tr> <td class="li red pr10" valign="top" style="color: #ED1556; width: 1px; padding-right: 10px;" width="1">&bull; </td> <td class="pb15" style="padding-bottom: 15px; width: 100%;" width="100%">~75% of commercial patients nationwide have unrestricted first-line coverage for <span class="no-wrap" style="white-space: nowrap;">ENSPRYNG&ndash;no</span> need for patients to fail other therapies<sup style="line-height: 0; font-size: 75%;">12§</sup> </td> </tr> <tr> <td class="li red pr10" valign="top" style="color: #ED1556; width: 1px; padding-right: 10px;" width="1">&bull; </td> <td>Beyond routine vaccinations,<sup style="line-height: 0; font-size: 75%;">¶</sup> no additional vaccines are required before starting ENSPRYNG. After proper training by a healthcare provider, patients can start self-administering ENSPRYNG at home or on the go<sup style="line-height: 0; font-size: 75%;">1</sup> </td> </tr> </tbody> </table> </td> </tr> <tr> <td class="ul footnote pb30" style="font-size: 11px; line-height: 13px; padding-bottom: 30px;"> <table role="presentation" border="0" cellpadding="0" cellspacing="0"> <tbody> <tr> <td class="li" valign="top" style="width: 1px; font-size: 11px; line-height: 13px;" width="1"><sup style="line-height: 0; font-size: 75%;">§</sup> </td> <td class="pb15" style="padding-bottom: 15px; font-size: 11px; line-height: 13px; width: 100%;" width="100%">Because drug coverage policies can change, please check with the health plan directly to confirm coverage for individual patients. Coverage policies current as of November 2024. </td> </tr> <tr> <td class="li" valign="top" style="width: 1px; font-size: 11px; line-height: 13px;" width="1"><sup style="line-height: 0; font-size: 75%;">¶</sup> </td> <td style="font-size: 11px; line-height: 13px;">According to immunization guidelines, all immunizations should be administered at least 4 weeks prior to initiation of ENSPRYNG for live or live-attenuated vaccines and, wherever possible, at least 2 weeks prior for non-live vaccines.<sup style="line-height: 0; font-size: 75%;">1</sup> </td> </tr> </tbody> </table> </td> </tr> <tr> <td class="pl5 pb30" style="padding-bottom: 30px; padding-left: 5px;"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="red-top" align="center" style="padding-top: 25px; padding-bottom: 15px; background-color: #ED1556; border-radius: 30px 30px 0 0;" bgcolor="#ED1556"> <a class="ghost-link" href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92f6&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=SdGI-eKp-7fZZs3Bq9bp2drgDRT9qMaXssYZRuRffrw" style="text-decoration: underline; color: #1c75bc;"><img class="white" src="https://aem.gene.com/content/dam/gene/email/enspryng/hcp/ens-h-nan-0002-1/icon-woman-2x.png" alt="Character of a woman looking bored" width="105" height="134" style="outline: none; text-decoration: none; -ms-interpolation-mode: bicubic; font-size: 10px; border: none; color: #ffffff; display: inline-block;"></a> </td> </tr> <tr> <td class="blue-bottom" style="padding-top: 40px; padding-bottom: 30px; padding-right: 30px; padding-left: 30px; background-color: #F4FBFD;" bgcolor="#F4FBFD"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="h1 pb15" style="font-size: 25px; line-height: 30px; color: #003479; font-weight: bold; padding-bottom: 15px;">Embrace the ordinary with ENSPRYNG </td> </tr> <tr> <td align="left"> <div> <!--[if mso]><v:roundrect xmlns:v="urn:schemas-microsoft-com:vml" xmlns:w="urn:schemas-microsoft-com:office:word" href="https://www.enspryng-hcp.com/contact-a-representative.html?c=ens-195d33da064" style="height:41px;v-text-anchor:middle;width:185px;" arcsize="73%" strokecolor="#ED1556" fillcolor="#ED1556" strokeweight="1px"><w:anchorlock/><center style="color:#ffffff;font-family:Arial,sans-serif;font-size:13px;font-weight:bold;">CONNECT WITH A REP</center></v:roundrect><![endif]--> <a href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92f7&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=jkcLocuogOKf0lL2dBMxRzs_I24IdVWEULKuxr1qEAU" style="background-color: #ED1556; border: 1px solid #ED1556; border-radius: 30px; color: #ffffff; display: inline-block; font-family: Arial,sans-serif; font-size: 13px; font-weight: bold; line-height: 41px; text-align: center; text-decoration: none; width: 185px; -webkit-text-size-adjust: none; mso-hide: all;">CONNECT WITH A REP</a> </div> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> <tr> <td class="footnote pb15 pl5" style="font-size: 11px; line-height: 13px; padding-bottom: 15px; padding-left: 5px;">AEs=adverse events; AQP4=aquaporin-4; BBB=blood-brain barrier; FDA=Food and Drug Administration; IgG=immunoglobulin G; <span class="no-wrap" style="white-space: nowrap;">IL-6=interleukin-6</span>; MOA=mechanism of action; <span class="no-wrap" style="white-space: nowrap;">NMOSD=neuromyelitis optica spectrum disorder.</span> </td> </tr> <tr> <td class="footnote pb15 pl5" style="font-size: 11px; line-height: 13px; padding-bottom: 15px; padding-left: 5px;">These data are for informational purposes only. Checking individual patients&rsquo; coverage is the responsibility of the patient and your office. The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and healthcare provider. Genentech makes no representation or guarantee concerning reimbursement, coverage, or co-pay for any service or item. </td> </tr> <tr> <td class="footnote pb15 pl5" style="font-size: 11px; line-height: 13px; padding-bottom: 15px; padding-left: 5px;">The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and healthcare provider. Genentech makes no representation or guarantee concerning coverage or reimbursement for any service or item. </td> </tr> <tr> <td class="footnote pl5" style="font-size: 11px; line-height: 13px; padding-left: 5px;">Genentech provides coverage and reimbursement services to patients to help them understand benefits, coverage, and reimbursement. Genentech provides these services to patients only after a healthcare provider has prescribed a Genentech product. </td> </tr> <tr class="mobile-only" style="display: none; max-height: 0px; overflow: hidden;"> <td class="mobile-only" style="display: none; max-height: 0px; overflow: hidden;"> <div class="mobile-only" style="display: none; max-height: 0px; overflow: hidden;"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="footnote pl5 pt25" style="font-size: 11px; line-height: 13px; padding-top: 25px; padding-left: 5px;"><strong>References: 1.</strong> ENSPRYNG [prescribing information]. South San Francisco, CA: Genentech, Inc. 2022. <strong>2.</strong> Wingerchuk DM, Hogancamp WF, O&rsquo;Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic&rsquo;s syndrome). <em>Neurology</em>. 1999;53(5):1107-1118. <strong>3.</strong> Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomized, double-blind, multicentre, placebo-controlled phase 3 trial. <em>Lancet Neurol</em>. 2020;19(5):402-412. <strong>4.</strong> Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. <em>N Engl J Med</em>. 2019;381(22):2114-2124. <strong>5.</strong> FDA approves Roche&rsquo;s ENSPRYNG for neuromyelitis optica spectrum disorder. Press release. Genentech; August 14, 2020. <strong>6.</strong> Anderson M, Levy M. Advances in the long-term treatment of neuromyelitis optica spectrum disorder. <em>J Cent Nerv Syst Dis</em>. 2024;16:1-11. <strong>7.</strong> Sellner J, Sitte HH, Rommer PS. Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: implications from immunology, the FcRn pathway and clinical experience. <em>Drug Discov Today</em>. 2021;26(7):1591-1601. <strong>8.</strong> Barros PO, Cassano T, Hygino J, et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. <em>Clin Exp Immunol</em>. 2016;183(3):480-489. <strong>9.</strong> Heo Y-A. Satralizumab: first approval. <em>Drugs</em>. 2020;80(14):1477-1482. <strong>10.</strong> Weinshenker B, Yeaman MR, de Seze J, et al. Long-term safety of satralizumab in adults with aquaporin-4-lgG-seropositive (AQP4-lgG+) neuromyelitis optica spectrum disorder (NMOSD). Presented at: the 75th Annual Meeting of the American Academy of Neurology; April 22-27, 2023; Boston, MA. <strong>11.</strong> Yamamura T, Weinshenker B, Yeaman MR, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. <span class="break-all" style="word-break: break-all;"><em>Mult Scler Relat Disord</em>.&nbsp;2022;66:104025.&nbsp;doi:10.1016/j.msard.2022.104025</span> <strong>12.</strong>&nbsp;Data&nbsp;on file. Genentech, Inc. South San Francisco, CA. </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> </td> <td class="safety" valign="top"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="247" style="width:247px;"> <tbody> <tr> <td class="rr-safety" style="padding-right: 25px; padding-left: 30px; border-left: 2px solid #91D5EB;"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="h2" style="font-size: 20px; line-height: 24px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Important Safety Information </td> </tr> <tr> <td class="h3" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Indication </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. </td> </tr> <tr> <td class="h3" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Contraindications </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">ENSPRYNG is contraindicated in patients with a known hypersensitivity to satralizumab or any of the inactive ingredients, an active hepatitis B infection, or active or untreated latent tuberculosis. </td> </tr> <tr> <td class="h3" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Warnings and Precautions </td> </tr> <tr> <td class="h3" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Infections </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">An increased risk of infections, including serious and potentially fatal infections, has been observed in patients treated with IL-6 receptor antagonists, including ENSPRYNG. The most common infections reported in a randomized clinical trial of patients treated with ENSPRYNG who were not on other chronic immunosuppressant therapies, and that occurred more often than in patients receiving placebo, were nasopharyngitis (12%) and cellulitis (10%). The most common infections in patients who were on an additional concurrent immunosuppressant, and that occurred more often than in patients receiving placebo, were nasopharyngitis (31%), upper respiratory infection (19%), and pharyngitis (12%). Delay ENSPRYNG administration in patients with an active infection, including localized infections, until the infection is resolved. </td> </tr> <tr> <td class="underline" style="text-decoration: underline;">Hepatitis B Virus (HBV) Reactivation </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">Risk of HBV reactivation has been observed with other immunosuppressant therapies. Patients with chronic HBV infection were excluded from clinical trials. Perform HBV screening in all patients before initiation of treatment with ENSPRYNG. Do not administer ENSPRYNG to patients with active hepatitis. For patients who are chronic carriers of HBV [HBsAg+] or are negative for HBsAg and positive for HB core antibody [HBcAb+], consult liver disease experts before starting and during treatment with ENSPRYNG. </td> </tr> <tr> <td class="underline" style="text-decoration: underline;">Tuberculosis </td> </tr> <tr> <td class="desktop-only p" style="padding-bottom: 15px;">Tuberculosis has occurred in patients treated with other IL-6 receptor antagonists. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating ENSPRYNG. Consider anti-tuberculosis therapy prior to initiation of ENSPRYNG in patients with a history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. </td> </tr> <tr> <td class="desktop-only h3 pb0" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 0;">Important Safety Information continued below </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> <tr> <td class="safety safety-cont" style="padding-right: 25px; padding-left: 25px; padding-bottom: 40px;"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="desktop-only footnote" style="font-size: 11px; line-height: 13px;"><strong>References: 1.</strong> ENSPRYNG [prescribing information]. South San Francisco, CA: Genentech, Inc. 2022. <strong>2.</strong> Wingerchuk DM, Hogancamp WF, O&rsquo;Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic&rsquo;s syndrome). <em>Neurology</em>. 1999;53(5):1107-1118. <strong>3.</strong> Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomized, double-blind, multicentre, placebo-controlled phase 3 trial. <em>Lancet Neurol</em>. 2020;19(5):402-412. <strong>4.</strong> Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. <em>N Engl J Med</em>. 2019;381(22):2114-2124. <strong>5.</strong> FDA approves Roche&rsquo;s ENSPRYNG for neuromyelitis optica spectrum disorder. Press release. Genentech; August 14, 2020. <strong>6.</strong> Anderson M, Levy M. Advances in the long-term treatment of neuromyelitis optica spectrum disorder. <em>J Cent Nerv Syst Dis</em>. 2024;16:1-11. <strong>7.</strong> Sellner J, Sitte HH, Rommer PS. Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: implications from immunology, the FcRn pathway and clinical experience. <em>Drug Discov Today</em>. 2021;26(7):1591-1601. <strong>8.</strong> Barros PO, Cassano T, Hygino J, et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. <em>Clin Exp Immunol</em>. 2016;183(3):480-489. <strong>9.</strong> Heo Y-A. Satralizumab: first approval. <em>Drugs</em>. 2020;80(14):1477-1482. <strong>10.</strong> Weinshenker B, Yeaman MR, de Seze J, et al. Long-term safety of satralizumab in adults with aquaporin-4-lgG-seropositive (AQP4-lgG+) neuromyelitis optica spectrum disorder (NMOSD). Presented at: the 75th Annual Meeting of the American Academy of Neurology; April 22-27, 2023; Boston, MA. <strong>11.</strong> Yamamura T, Weinshenker B, Yeaman MR, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. <em>Mult Scler Relat Disord</em>. 2022;66:104025. doi:10.1016/j.msard.2022.104025 <strong>12.</strong>&nbsp;Data&nbsp;on file. Genentech, Inc. South San Francisco, CA. </td> </tr> <tr> <td class="desktop-only h2 pb15 pt30" style="font-size: 20px; line-height: 24px; color: #242A74; font-weight: bold; padding-top: 30px; padding-bottom: 15px;">Important Safety Information </td> </tr> <tr> <td class="desktop-only underline" style="text-decoration: underline;">Tuberculosis (cont&rsquo;d) </td> </tr> <tr> <td class="desktop-only p" style="padding-bottom: 15px;">Consult infectious disease experts regarding whether initiating anti-tuberculosis therapy is appropriate before starting treatment. Patients should be monitored for the development of signs and symptoms of tuberculosis with ENSPRYNG, even if initial tuberculosis testing is negative. </td> </tr> <tr class="mobile-only" style="display: none; max-height: 0px; overflow: hidden;"> <td class="mobile-only" style="display: none; max-height: 0px; overflow: hidden;"> <div class="mobile-only" style="display: none; max-height: 0px; overflow: hidden;"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td class="p" style="padding-bottom: 15px;">Tuberculosis has occurred in patients treated with other IL-6 receptor antagonists. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating ENSPRYNG. Consider anti-tuberculosis therapy prior to initiation of ENSPRYNG in patients with a history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consult infectious disease experts regarding whether initiating anti-tuberculosis therapy is appropriate before starting treatment. Patients should be monitored for the development of signs and symptoms of tuberculosis with ENSPRYNG, even if initial tuberculosis testing is negative. </td> </tr> </tbody> </table> </div> </td> </tr> <tr> <td class="underline" style="text-decoration: underline;">Vaccinations </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">Live or live-attenuated vaccines should not be given concurrently with ENSPRYNG because clinical safety has not been established. Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of ENSPRYNG for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of ENSPRYNG for non-live vaccines. </td> </tr> <tr> <td class="h3" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Elevated Liver Enzymes </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">Mild and moderate elevations of liver enzymes have been observed in patients treated with ENSPRYNG at a higher incidence than in patients receiving placebo. ALT and AST levels should be monitored every 4 weeks for the first 3 months of treatment, followed by every 3 months for one year, and thereafter, as clinically indicated. </td> </tr> <tr> <td class="h3" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Decreased Neutrophil Counts </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">Decreases in neutrophil counts were observed in patients treated with ENSPRYNG at a higher incidence than placebo. Neutrophil counts should be monitored 4 to 8 weeks after initiation of therapy, and thereafter at regular clinically determined intervals. </td> </tr> <tr> <td class="h3" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Hypersensitivity Reactions </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">Hypersensitivity reactions, including rash, urticaria, and fatal anaphylaxis, have occurred with other IL-6 receptor antagonists. </td> </tr> <tr> <td class="h3" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Use in Specific Populations </td> </tr> <tr> <td class="h3" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Pregnancy </td> </tr> <tr> <td class="h3 underline" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; text-decoration: underline; padding-bottom: 15px;">Pregnancy Exposure Registry </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ENSPRYNG during pregnancy. Healthcare providers are encouraged to register patients and pregnant women are encouraged to register themselves by calling <a class="black no-underline" href="tel:1-833-277-9338" style="color: #000000; text-decoration: none; white-space: nowrap;">1-833-277-9338</a>. </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">There are no adequate data on the developmental risk associated with the use of ENSPRYNG in pregnant women. In an animal reproduction study, no adverse effects on maternal animals or fetal development were observed in pregnant monkeys and their offspring, with administration of ENSPRYNG at doses up to 50 mg/kg/week. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2 &ndash; 4% and 15 &ndash; 20%, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. </td> </tr> <tr> <td class="h3" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Lactation </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">No information is available on the presence of ENSPRYNG in human milk, the effects of ENSPRYNG on the breastfed infant, or the effects of ENSPRYNG on milk production. ENSPRYNG was excreted in the milk of lactating monkeys administered ENSPRYNG throughout pregnancy. Human IgG is excreted in human milk and the potential for absorption in the infant is unknown. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for ENSPRYNG and any potential adverse effects on the breastfed infant from ENSPRYNG or from the underlying maternal condition. </td> </tr> <tr> <td class="h3" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Pediatric Use </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">Safety and effectiveness in pediatric patients have not been established. </td> </tr> <tr> <td class="h3" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Geriatric Use </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">Clinical studies of ENSPRYNG did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. However, population pharmacokinetic analyses in patients with NMOSD did not show that age affected the pharmacokinetics of ENSPRYNG. In general, caution should be used when dosing the elderly, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy. </td> </tr> <tr> <td class="h3" style="font-size: 18px; line-height: 22px; color: #242A74; font-weight: bold; padding-bottom: 15px;">Most Common Adverse Reactions </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">The most common adverse reactions (&ge;15% in either trial) were nasopharyngitis (31%), headache (27%), upper respiratory tract infection (19%), rash (17%), arthralgia (17%), extremity pain (15%), gastritis (15%), fatigue (15%), and nausea (15%). </td> </tr> <tr> <td class="p" style="padding-bottom: 15px;">You may report side effects to the FDA at <a class="red" href="tel:1-800-332-1088" style="text-decoration: underline; color: #ED1556; white-space: nowrap;">(800) FDA-1088</a> or <a class="red" href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92f8&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=m7GzyGgUXnz3YYT-WwQe1r7vY_nOpDNh-ito2lBJbIw" style="text-decoration: underline; color: #ED1556;">www.fda.gov/medwatch</a>. You may also report side effects to Genentech at <a class="red" href="tel:1-888-835-2555" style="text-decoration: underline; color: #ED1556; white-space: nowrap;">(888) 835-2555</a>. </td> </tr> <tr> <td>For additional safety information, please see the full <a class="red" href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92f9&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=-1SCbKtSv3rwIWpx2Ln0i6Kw0PPU6vbg_bNJ4xH5PLM" style="text-decoration: underline; color: #ED1556;">Prescribing Information</a> and <a class="red" href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92fa&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=Hu37oV_cy9rvO4q0TQM7YoVqm2uH7ACcSk--H7r7vJE" style="text-decoration: underline; color: #ED1556;">Medication Guide</a>. </td> </tr> <tr> <td> 
PDF: Subject Line Option 3: An ordinary email about NMOSD
Email: 
PDF: Subject Line Option 4: Explore the established safety of ENSPRYNG® (satralizumab)
Email:  </td> </tr> </tbody> </table> </td> </tr> <tr> <td class="footer" style="padding-right: 25px; padding-left: 25px; padding-top: 40px; padding-bottom: 40px; border-top: 1px solid #BBBBBB;"> <table align="center" role="presentation" border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td style="color: #182628; font-size: 12px; line-height: 14px;"> <a class="ghost-link" href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92fb&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=W1nHlc7HAR2CXniTVFIA-u3NDh7Z7hfqn53NSnRPaVE" style="text-decoration: underline;"><img src="https://aem.gene.com/content/dam/gene/email/enspryng/hcp/ens-h-nan-0002-1/logo-gene-2x.png" alt="Genentech logo" width="122" height="32" style="outline: none; text-decoration: none; -ms-interpolation-mode: bicubic; font-size: 10px; border: none; display: inline-block;"></a> </td> </tr> <tr> <td class="legal" style="padding-top: 50px; padding-bottom: 55px; color: #182628; font-size: 12px; line-height: 14px;"> <table role="presentation" border="0" cellpadding="0" cellspacing="0"> <tbody> <tr> <td class="block pr40 m-pr0 m-pb20" style="padding-right: 40px; color: #182628; font-size: 12px; line-height: 14px;"> <a href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92fc&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=RMOEuB_05FAm1-m4M9as_vOmJyOw90QzDXWBYUbAElA" style="color: #003087; font-weight: bold; text-decoration: underline;">Contact Us</a> </td> <td class="block pr40 m-pr0 m-pb20" style="padding-right: 40px; color: #182628; font-size: 12px; line-height: 14px;"> <a href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92fd&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=eyRcg20YU9UGzpNYger1EACgAYEt-e2M1xObs8IvWJQ" style="color: #003087; font-weight: bold; text-decoration: underline;">Privacy Policy</a> </td> <td class="block pr40 m-pr0 m-pb20" style="padding-right: 40px; color: #182628; font-size: 12px; line-height: 14px;"> <a href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92fe&e=cDE9ZW5zLTE5NWQzM2RhMDY0&s=9sOi1wrAB_NoOerAMU-CPoCfT2cnGQ5UoWI4DfjX1KU" style="color: #003087; font-weight: bold; text-decoration: underline;">Terms and Conditions</a> </td> <td class="block" style="color: #182628; font-size: 12px; line-height: 14px;"> <a href="https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,116d92ff&e=cDE9aXBtLnVhdC5xYUBnbWFpbC5jb20mcDI9RU5TQkhDUFJNJnAzPWVucy0xOTVkMzNkYTA2NA&s=LKNy7oi40aiA5fyNV5ww9dYA_jMB0_TOFd9AChItv7A" style="color: #003087; font-weight: bold; text-decoration: underline;">Unsubscribe</a> </td> </tr> </tbody> </table> </td> </tr> <tr> <td class="pb10" style="padding-bottom: 10px; color: #182628; font-size: 12px; line-height: 14px;"> This commercial email is brought to you by Genentech USA, Inc. </td> </tr> <tr> <td class="pb10" style="padding-bottom: 10px; color: #182628; font-size: 12px; line-height: 14px;"> This email is intended for US residents only </td> </tr> <tr> <td class="pb10" style="padding-bottom: 10px; color: #182628; font-size: 12px; line-height: 14px;"> © 2025 Genentech USA, Inc. All rights reserved. </td> </tr> <tr> <td style="color: #182628; font-size: 12px; line-height: 14px;"> Genentech USA, Inc. 1 DNA Way South San Francisco, CA <span class="no-wrap" style="white-space: nowrap;">94080-4990</span> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <div style="display:none;white-space:nowrap;font:15px courier;line-height:0;"> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </div> <img height='0' width='0' alt='' src='https://t.e.genentech.com/r/?id=h14705e2,23a1d65e,1'/></body></html>
